Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007803
Filing Date
2025-05-15
Accepted
2025-05-15 07:25:28
Documents
71
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zbio-20250331x10q.htm   iXBRL 10-Q 2344482
2 EX-31.1 zbio-20250331xex31d1.htm EX-31.1 15573
3 EX-31.2 zbio-20250331xex31d2.htm EX-31.2 15177
4 EX-32.1 zbio-20250331xex32d1.htm EX-32.1 8167
5 EX-32.2 zbio-20250331xex32d2.htm EX-32.2 7999
6 GRAPHIC zbio-20250331x10q004.jpg GRAPHIC 6769
  Complete submission text file 0001558370-25-007803.txt   7118558

Data Files

Seq Description Document Type Size
7 EX-101.SCH zbio-20250331.xsd EX-101.SCH 42744
8 EX-101.CAL zbio-20250331_cal.xml EX-101.CAL 48450
9 EX-101.DEF zbio-20250331_def.xml EX-101.DEF 144590
10 EX-101.LAB zbio-20250331_lab.xml EX-101.LAB 390729
11 EX-101.PRE zbio-20250331_pre.xml EX-101.PRE 282635
74 EXTRACTED XBRL INSTANCE DOCUMENT zbio-20250331x10q_htm.xml XML 909380
Mailing Address 852 WINTER STREET, SUITE 250 WALTHAM MA 02451
Business Address 852 WINTER STREET, SUITE 250 WALTHAM MA 02451 857-271-2954
Zenas BioPharma, Inc. (Filer) CIK: 0001953926 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42270 | Film No.: 25948700
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)